Stocks and Investing
Stocks and Investing
Thu, May 9, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Ami Fadia Reiterated (ACAD) at Strong Buy and Held Target at $30 on, May 9th, 2024
Ami Fadia of Needham, Reiterated "ACADIA Pharmaceuticals Inc." (ACAD) at Strong Buy and Held Target at $30 on, May 9th, 2024.
Ami has made no other calls on ACAD in the last 4 months.
There are 9 other peers that have a rating on ACAD. Out of the 9 peers that are also analyzing ACAD, 2 agree with Ami's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Jay Olson of "Oppenheimer" Maintained at Hold and Held Target at $19 on, Monday, May 6th, 2024
- Tazeen Ahmad of "B of A Securities" Maintained at Hold with Decreased Target to $30 on, Tuesday, March 12th, 2024
These are the ratings of the 7 analyists that currently disagree with Ami
- Ashwani Verma of "UBS" Maintained at Strong Buy with Decreased Target to $27 on, Tuesday, April 30th, 2024
- Tessa Romero of "JP Morgan" Maintained at Buy with Decreased Target to $25 on, Monday, March 25th, 2024
- Jeffrey Hung of "Morgan Stanley" Maintained at Buy with Decreased Target to $30 on, Wednesday, March 13th, 2024
- Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $30 on, Tuesday, March 12th, 2024
- Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $39 on, Tuesday, March 12th, 2024
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $33 on, Tuesday, March 12th, 2024
- Joseph Stringer of "Needham" Upgraded from Hold to Strong Buy and Held Target at $37 on, Wednesday, January 24th, 2024
Contributing Sources